2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro]

What the CMS Formulary Data Shows for 2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro]

Per the CMS 2026 Part D formulary file, 2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro] (RxNorm concept RXCUI 2055650, generic name lanadelumab-flyo) appears on 31 distinct formulary files spanning 341 Medicare Part D plan offerings - 6.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 4.7.

Real-world access to 2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro] depends on utilization management as much as tier placement: 93.5% of covering formularies require prior authorization. 0% require step therapy. 71% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 27 Part D beneficiaries filled 2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro] in 2023, with total plan-and-beneficiary spending of $5,832,614 and an average per-beneficiary annual cost of $216,022.73. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 2 ML lanadelumab-flyo 150 MG/ML Injection [Takhzyro] today.